Early-Stage Primary Bone Lymphoma: A Retrospective, Multicenter Rare Cancer Network (RCN) Study.

Détails

ID Serval
serval:BIB_D5857DBFA0C5
Type
Article: article d'un périodique ou d'un magazine.
Collection
Publications
Institution
Titre
Early-Stage Primary Bone Lymphoma: A Retrospective, Multicenter Rare Cancer Network (RCN) Study.
Périodique
International Journal of Radiation Oncology, Biology, Physics
Auteur(s)
Cai L., Stauder M.C., Zhang Y.J., Poortmans P., Li Y.X., Constantinou N., Thariat J., Kadish S.P., Nguyen T.D., Kirova Y.M., Ghadjar P., Weber D.C., Bertran V.T., Ozsahin M., Mirimanoff R.O.
ISSN
1879-355X (Electronic)
ISSN-L
0360-3016
Statut éditorial
Publié
Date de publication
2012
Volume
83
Numéro
1
Pages
284-291
Langue
anglais
Notes
Publication types: Journal Article
Résumé
PURPOSE: Primary bone lymphoma (PBL) represents less than 1% of all malignant lymphomas. In this study, we assessed the disease profile, outcome, and prognostic factors in patients with Stages I and II PBL.¦PATIENTS AND METHODS: Thirteen Rare Cancer Network (RCN) institutions enrolled 116 consecutive patients with PBL treated between 1987 and 2008 in this study. Eighty-seven patients underwent chemoradiotherapy (CXRT) without (78) or with (9) surgery, 15 radiotherapy (RT) without (13) or with (2) surgery, and 14 chemotherapy (CXT) without (9) or with (5) surgery. Median RT dose was 40 Gy (range, 4-60). The median number of CXT cycles was six (range, 2-8). Median follow-up was 41 months (range, 6-242).¦RESULTS: The overall response rate at the end of treatment was 91% (complete response [CR] 74%, partial response [PR] 17%). Local recurrence or progression was observed in 12 (10%) patients and systemic recurrence in 17 (15%). The 5-year overall survival (OS), lymphoma-specific survival (LSS), and local control (LC) were 76%, 78%, and 92%, respectively. In univariate analyses (log-rank test), favorable prognostic factors for OS and LSS were International Prognostic Index (IPI) score ≤1 (p = 0.009), high-grade histology (p = 0.04), CXRT (p = 0.05), CXT (p = 0.0004), CR (p < 0.0001), and RT dose >40 Gy (p = 0.005). For LC, only CR and Stage I were favorable factors. In multivariate analysis, IPI score, RT dose, CR, and CXT were independently influencing the outcome (OS and LSS). CR was the only predicting factor for LC.¦CONCLUSION: This large multicenter retrospective study confirms the good prognosis of early-stage PBL treated with combined CXRT. An adequate dose of RT and complete CXT regime were associated with better outcome.
Pubmed
Web of science
Open Access
Oui
Création de la notice
12/05/2012 9:41
Dernière modification de la notice
20/08/2019 16:55
Données d'usage